Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:CXF NASDAQ:ME TSE:NEPT NASDAQ:RGC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCXFCI Canadian Convertible Bond ETF CommonC$10.62C$10.53C$10.15▼C$10.98C$60.50M0.75,039 shs1,219 shsME23andMe$0.61$0.50$0.53▼$9.57$16.27M1.191.57 million shsN/ANEPTNeptune Wellness SolutionsC$0.00C$0.14▼C$4.74C$15.73MN/A92,998 shs10,366 shsRGCRegencell Bioscience$18.83$26.77$9.39▼$83.60$9.31B1.6687,625 shs85,067 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCXFCI Canadian Convertible Bond ETF Common0.00%0.00%-0.47%+1.05%+4.02%ME23andMe0.00%0.00%0.00%0.00%+21.75%NEPTNeptune Wellness Solutions0.00%0.00%0.00%0.00%0.00%RGCRegencell Bioscience0.00%-5.80%-34.11%-16.98%+1,882,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCXFCI Canadian Convertible Bond ETF CommonC$10.62C$10.53C$10.15▼C$10.98C$60.50M0.75,039 shs1,219 shsME23andMe$0.61$0.50$0.53▼$9.57$16.27M1.191.57 million shsN/ANEPTNeptune Wellness SolutionsC$0.00C$0.14▼C$4.74C$15.73MN/A92,998 shs10,366 shsRGCRegencell Bioscience$18.83$26.77$9.39▼$83.60$9.31B1.6687,625 shs85,067 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCXFCI Canadian Convertible Bond ETF Common0.00%0.00%-0.47%+1.05%+4.02%ME23andMe0.00%0.00%0.00%0.00%+21.75%NEPTNeptune Wellness Solutions0.00%0.00%0.00%0.00%0.00%RGCRegencell Bioscience0.00%-5.80%-34.11%-16.98%+1,882,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCXFCI Canadian Convertible Bond ETF Common 0.00N/AN/AN/AME23andMe 0.00N/AN/AN/ANEPTNeptune Wellness Solutions 0.00N/AN/AN/ARGCRegencell Bioscience 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest NEPT, CXF, RGC, and ME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2026RGCRegencell Bioscience Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCXFCI Canadian Convertible Bond ETF CommonN/AN/AN/AN/AN/AN/AME23andMe$208.78M0.08$0.65 per share0.93$2.34 per share0.26NEPTNeptune Wellness SolutionsC$48.80M0.00N/A1.71C$8.66 per share0.00RGCRegencell BioscienceN/AN/AN/AN/A$0.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCXFCI Canadian Convertible Bond ETF CommonN/AN/AN/AN/AN/AN/AN/AN/AN/AME23andMe-$666.70M-$15.45N/AN/AN/A-183.39%-170.07%-62.13%N/ANEPTNeptune Wellness SolutionsN/A-C$24.16N/AN/AN/AN/AN/AN/AN/ARGCRegencell Bioscience-$3.58MN/AN/AN/AN/AN/AN/AN/AN/ALatest NEPT, CXF, RGC, and ME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026RGCRegencell BioscienceN/A-$0.0050N/A-$0.0050N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCXFCI Canadian Convertible Bond ETF CommonC$0.484.52%N/AN/AN/AME23andMeN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/ARGCRegencell BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCXFCI Canadian Convertible Bond ETF CommonN/AN/AN/AME23andMeN/A1.050.91NEPTNeptune Wellness Solutions23.591.230.54RGCRegencell BioscienceN/A1.41N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCXFCI Canadian Convertible Bond ETF CommonN/AME23andMe36.10%NEPTNeptune Wellness SolutionsN/ARGCRegencell Bioscience0.13%Insider OwnershipCompanyInsider OwnershipCXFCI Canadian Convertible Bond ETF CommonN/AME23andMe26.32%NEPTNeptune Wellness SolutionsN/ARGCRegencell BioscienceN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCXFCI Canadian Convertible Bond ETF Common905.70 millionN/ANot OptionableME23andMe77026.83 million19.77 millionNot OptionableNEPTNeptune Wellness Solutions1307.99 millionN/ANot OptionableRGCRegencell Bioscience10494.49 millionN/AN/ANEPT, CXF, RGC, and ME HeadlinesRecent News About These CompaniesREGENCELL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action - RGCJune 14 at 6:17 PM | newsfilecorp.comNBronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor HarmJune 14 at 12:00 PM | globenewswire.comREGENCELL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important June 23 Deadline in Securities Class Action - RGCJune 13 at 11:31 AM | markets.businessinsider.comREGENCELL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important June 23 Deadline in Securities Class Action - RGCJune 13 at 9:19 AM | newsfilecorp.comNRGC EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026June 13 at 8:20 AM | globenewswire.comRGC Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud LawsuitJune 12 at 5:51 PM | prnewswire.comRegencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitJune 12 at 3:54 PM | prnewswire.comBragar Eagel & Squire, P.C. Reminds Regencell Bioscience Holdings Limited (NASDAQ:RGC) Investors They Have Until June 23rd to Contact the Firm Seeking Lead Plaintiff RoleJune 12 at 12:35 PM | globenewswire.comREGENCELL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100Kto Secure Counsel Before Important June 23 Deadline in Securities Class Action – RGCJune 12 at 12:26 PM | globenewswire.comRGC Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regencell Bioscience Holdings Limited Securities Lawsuit - Contact The Gross Law FirmJune 12 at 11:46 AM | globenewswire.comREGENCELL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important June 23 Deadline in Securities Class Action - RGCJune 11, 2026 | newsfilecorp.comNRGC SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026June 11, 2026 | newsfilecorp.comNDeadline Alert: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitJune 11, 2026 | globenewswire.comLost Money on Regencell Bioscience Holdings Limited (RGC)? Join Class Action Suit Seeking Recovery - Contact SueWallStJune 11, 2026 | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGCJune 11, 2026 | prnewswire.comREGENCELL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important June 23 Deadline in Securities Class Action - RGCJune 10, 2026 | newsfilecorp.comNDEADLINE ALERT for RGC, SES, FSK, GPK: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class ActionsJune 10, 2026 | globenewswire.comDEADLINE ALERT for LKQ, RGC, and GLOB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersJune 10, 2026 | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor HarmJune 10, 2026 | globenewswire.comRGC INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Deadline on June 23, 2026June 10, 2026 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026Target the Red-Hot Spin-Off and Merger Space With These ETFsBy Nathan Reiff | May 17, 2026How the Memory Shortage Is Crushing the Gaming IndustryBy Dan Schmidt | June 4, 2026Gen Z Trends Make These 3 Stocks Worth WatchingBy Chris Markoch | June 4, 2026NEPT, CXF, RGC, and ME Company DescriptionsCI Canadian Convertible Bond ETF Common TSE:CXFC$10.62 0.00 (0.00%) As of 06/12/2026 10:05 AM EasternThe investment objectives of First Asset Canadian Convertible Bond ETF are to provide holders with (i) quarterly cash distributions, and (ii) the opportunity for capital appreciation by investing on a capitalization weighted basis in a portfolio (the Convertible Portfolio) of Convertible Bonds of Canadian issuers. The Convertible ETF will invest on a capitalization weighted basis in Convertible Bonds which meet the Eligibility Criteria. Capitalization weightings are determined on the basis of a Convertible Bonds relative market capitalization to the total market capitalization of Convertible Bonds included in the Convertible Portfolio, on initial investment and on quarterly rebalancings.23andMe NASDAQ:ME23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.Neptune Wellness Solutions TSE:NEPTNeptune Wellness Solutions Inc. operates as an integrated health and wellness company in Canada, the United States, and internationally. It builds a portfolio of lifestyle brands and consumer packaged goods products under the Biodroga, Forest Remedies, Ocean Remedies, Neptune Wellness, Mood Ring, PanHash, Sprout, Nosh, MaxSimil, and NurturMe brands. The company also offers turnkey product development and supply chain solutions to business customers in various health and wellness verticals, including nutraceuticals, beauty and personal care products, and organic foods and beverages. In addition, it is involved in the extraction, purification, formulation, and manufacturing of health and wellness products. Further, the company offers Maxsimil, an omega-3 fatty acid delivery technology that uses enzymes that mimic the natural human digestive system to predigest omega-3 fatty acids. It has a collaboration agreement with International Flavors & Fragrances Inc. to co-develop hemp-derived CBD products for the mass retail, and health and wellness markets. The company was incorporated in 1998 and is headquartered in Laval, Canada.Regencell Bioscience NASDAQ:RGC$18.83 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$19.03 +0.20 (+1.05%) As of 09:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Meta to Follow Alphabet's Footsteps? What an Equity Raise Could Mean Viasat's Orbiting Profits: Space Force Jackpot? What to Expect From Q2 Earnings as Tech Strength Broadens ERock IPO: A $1.3B Power Play Solution Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
